Aadi intends to use the net proceeds from the private placement to fund certain upfront payments under its license agreement with WuXi Biologics (Shanghai FX) Co., Ltd. and for working capital and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback